Echo Therapeutics

Company Snapshot: Echo Therapeutics

Last Change Volume High Low

Company Overview

Echo Therapeutics is developing its non-invasive, wireless, continuous glucose monitoring (CGM) system. A significant opportunity exists for the Company’s CGM to be used in the outpatient diabetes market and in the fitness, weight loss and personal lifestyle wearable-health space. A longer-term opportunity also exists in the hospital settings. Echo developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.

Client News

  1. Dec 21 2016 Echo Therapeutics Announces Dismissal of Federal Court Action
  2. Dec 12 2016 Echo Therapeutics Announces Federal Court's Denial Of Preliminary Injunction And Lifting Of Temporary Restraining Order
  3. Aug 12 2016 Echo Therapeutics, Inc. Announces Second Quarter 2016 Financial Results
  4. Jul 8 2016 Echo Therapeutics Common Stock to Transition from NASDAQ to OTCQB